스테이블코인 디벨롭먼트(NBY) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

⏳

최근 시세가 확인되지 않는 종목 최근 5거래일간 시세가 수집되지 않았습니다. 거래 정지·상장 폐지 여부를 확인 중입니다.

NBY

Stablecoin Development Corp

$1.95

+0.00 +0.00%

스테이블코인 디벨롭먼트(NBY) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$40M

스몰캡

P/E

배당수익률

없음

52주 위치

저점 +76% · 고점 -98%

애널리스트

적극 매수

Fundamental health

vs. Biotechnology· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 33%

밸류에이션

데이터 부족

재무 안정

Top 40%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-7.43	Insider Own ⓘ	95.11%	Shs Outstand ⓘ	26.6M	Perf Week ⓘ	-
Market Cap ⓘ	0.04B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	-	Shs Float ⓘ	1.3M	Perf Month ⓘ	43.38%
Enterprise Value ⓘ	0.04B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	5.34%	Short Float ⓘ	49.78%	Perf Quarter ⓘ	-96.94%
Income ⓘ	-0.01B	P/S ⓘ	14.11	EPS this Y ⓘ	-	Inst Trans ⓘ	77.46%	Short Ratio ⓘ	1.19	Perf Half Y ⓘ	-62.86%
Sales ⓘ	0.00B	P/B ⓘ	-	EPS next 5Y ⓘ	-	ROA ⓘ	-215.92%	Short Interest ⓘ	0.65M	Perf YTD ⓘ	-93.09%
Book/sh ⓘ	-2.23	P/C ⓘ	17.29	EPS past 3/5Y ⓘ	85.2% 68.77%	ROE ⓘ	-587.58%	52W High ⓘ	-98.05% ($99.75)	Perf Year ⓘ	3.15%
Cash/sh ⓘ	0.11	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-	ROIC ⓘ	-395.68%	52W Low ⓘ	75.68% ($1.11)	Perf 3Y ⓘ	-99.01%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	95.81%	Gross Margin ⓘ	51.27%	Volatility(W/M) ⓘ	15.11% 17.86%	Perf 5Y ⓘ	-99.95%
Dividend TTM ⓘ	-	EV/Sales ⓘ	15.17	Sales Y/Y TTM ⓘ	-74.73%	Oper. Margin ⓘ	-249.12%	ATR (14) ⓘ	0.72	Perf 10Y ⓘ	-99.98%
Dividend Ex-Date ⓘ	2025/9/30	Quick Ratio ⓘ	1.98	EPS Q/Q ⓘ	63.18%	Profit Margin ⓘ	-285.09%	RSI (14) ⓘ	42.51	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.98	Sales Q/Q ⓘ	-78.66%	SMA20 ⓘ	40.19% ($1.39)	Beta ⓘ	0.46	Target Price ⓘ	$4.25
Payout ⓘ	-	Debt/Eq ⓘ	0.6	Earnings ⓘ	2025/11/7	SMA50 ⓘ	-51.77% ($4.04)	Rel Volume ⓘ	0	Prev Close ⓘ	$1.95
Employees ⓘ	4	LT Debt/Eq ⓘ	0.25	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	-78.08% ($8.9)	Avg Volume(3M) ⓘ	0.55M	Price ⓘ	$1.95
IPO ⓘ	2007/10/26	Option/Short ⓘ	No/No			Trades ⓘ	0	Volume ⓘ	-	Change ⓘ	-

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Stablecoin Development Corp (NBY) Investment Analysis

What kind of company is Stablecoin Development Corp?

스테이블코인 디벨롭먼트(NBY) 방어주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

🔬 Stablecoin Development (NBY) is a U.S. bio-healthcare venture company focused on the research and development of specialty pharmaceuticals for ophthalmic diseases, wound cleansing, and infection prevention, as well as specialized antimicrobial cleansing solutions, with proprietary technology for dry eye treatment and infection prevention.

Learn more about Stablecoin Development Corp →

Market Cap

$0.0B

Approx. KRW 0.1 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5026

Employees4people

IPO2007/10/26

Current Price$1.95 ≈ 2,672원

AMEX · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2025년 11월 7일 (금) · 장 시작 전

🎯 Ex-div 2025년 9월 30일 (화)

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-249.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-285.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

51.3%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 초소형주 Median 53.4% · Bottom 49%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-587.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-215.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-395.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.60

✓ Average

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

1.98

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

1.98

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$4.25

현재가 대비 +117.9%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth

Mid-range within the industry

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+85.2%

우수

My positionTop 25%

Low range Average High range

방어주 초소형주 Median 30.0% · Top 9%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+68.8%

우수

My positionTop 5%

Low range Average High range

방어주 초소형주 Median 16.4% · Top 3%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-78.7%

부진

My positionBottom 25%

Low range Average High range

방어주 초소형주 Median -4.5% · Bottom 13%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -168%p below the market

NBY -100.0% · S&P 500 +68.4%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-168.3%p

Significantly behind the market

vs Health Care (XLV)

-124.5%p

Significantly behind the sector average

1-year basis

vs S&P 500

-12.9%p

behind the market

vs Health Care (XLV)

-16.6%p

behind the sector average

Rank among peers

5-year return Bottom 10% Based on 245 peers

1-year return Top 23% Based on 315 peers

Current position within 52-week range

Low (-75.7%p) High (-98.0%p)

Current price is 75.7% above the 52-week low and 98.0% below the 52-week high

Recent risk (last 60 trading days)

Max drawdown

-86.3%

Annualized volatility

314.3%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 88-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-05-15

Uptrend zone

Current price $1.64 above the midline ($1.46). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-05-15

Neutral zone — weak trend

MACD -0.057 · Signal -0.145 · Hist 0.088. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-05-15

Bearish zone

RSI 49.1 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 62.9.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

In line with peers on Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🧾 Vs. Sales Mid-range

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

14.11x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 초소형주 median 11.24x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$4.25 vs. current price +117.9%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow shows some pressure

Institutional net buying +77.5% · Short interest very high 49.8% · Short interest up +37.6pp over last 60d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

+77.5%

Institutions large net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 5.3%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 95.1%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

49.8%

Very high — strong short-side pressure

전체 시장 Median -%

Past 60 days 📈 +37.6%p increase

Short interest days to cover

1.2 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 26.6M주

Float (tradable shares) 1.3M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 60 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
NBY This Stock	$39.9M	-	-	-587.58% ▼	-	+0.0%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 스테이블코인 디벨롭먼트(NBY)?

스테이블코인 디벨롭먼트(NBY) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of NBY?

The market cap of NBY is approximately $40M, ranking 5,026 within its sector.

What is the 52-week high and low for NBY?

NBY has recorded a 52-week high of $99.75 and a low of $1.11.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.